Vericel Corporation (NASDAQ:VCEL - Get Free Report) Director Robert Md Zerbe sold 2,000 shares of the business's stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $57.88, for a total value of $115,760.00. Following the completion of the transaction, the director directly owned 32,995 shares of the company's stock, valued at approximately $1,909,750.60. This trade represents a 5.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Vericel Stock Down 3.4%
VCEL opened at $57.42 on Friday. The stock has a market capitalization of $2.93 billion, a price-to-earnings ratio of 89.72 and a beta of 1.08. Vericel Corporation has a twelve month low of $28.95 and a twelve month high of $59.75. The company has a 50-day simple moving average of $42.45 and a 200 day simple moving average of $39.30.
Vericel (NASDAQ:VCEL - Get Free Report) last released its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.06 by $0.21. Vericel had a net margin of 10.27% and a return on equity of 9.09%. The firm had revenue of $85.37 million for the quarter, compared to analyst estimates of $77.95 million. During the same period last year, the firm earned $0.10 EPS. The business's quarterly revenue was up 26.5% compared to the same quarter last year. Sell-side analysts anticipate that Vericel Corporation will post 0.78 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on VCEL shares. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Vericel in a report on Thursday, October 29th. Wall Street Zen raised shares of Vericel from a "buy" rating to a "strong-buy" rating in a research note on Saturday, November 7th. Stephens lifted their price objective on shares of Vericel from $55.00 to $68.00 and gave the company an "overweight" rating in a research note on Tuesday. TD Cowen boosted their price objective on shares of Vericel from $55.00 to $58.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Finally, Zacks Research upgraded Vericel from a "hold" rating to a "strong-buy" rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Vericel presently has an average rating of "Buy" and an average price target of $62.00.
Read Our Latest Report on VCEL
Institutional Trading of Vericel
Large investors have recently bought and sold shares of the business. MCF Advisors LLC boosted its stake in Vericel by 293.0% in the second quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company's stock valued at $35,000 after buying an additional 583 shares in the last quarter. Ameritas Advisory Services LLC acquired a new position in Vericel during the second quarter worth about $36,000. Hantz Financial Services Inc. raised its stake in Vericel by 24.8% during the third quarter. Hantz Financial Services Inc. now owns 1,194 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 237 shares in the last quarter. Allworth Financial LP acquired a new position in Vericel during the second quarter worth about $60,000. Finally, Integrated Wealth Concepts LLC bought a new position in shares of Vericel in the second quarter worth about $72,000.
Vericel Company Profile
(
Get Free Report)
Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient's own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
